Lamberti Jessica, Memoli Domenico, Montico Barbara, Silvestro Francesco, Guerrieri Roberto, Colizzi Francesca, Weisz Alessandro, Salvati Annamaria, Fratta Elisabetta, Nassa Giovanni
Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, (SA), Italy.
Immunopathology and Cancer Biomarkers Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Sci Data. 2025 Sep 2;12(1):1538. doi: 10.1038/s41597-025-05807-x.
Cutaneous melanoma (CM), with a continuously rising incidence worldwide, represents the most aggressive type of skin cancer, and it leads to the majority of skin cancer-related deaths. Approximately 50% of CM carry the activating BRAF mutation and, although BRAF inhibitors have demonstrated clinical efficacy, most patients often develop early resistance to treatment. Aberrant expression of non-coding RNAs (ncRNAs), which represent less than 2% of the entire transcriptome, has been implicated in CM development and progression. By using BRAF-mutant CM in vitro and in vivo models, we have recently demonstrated that the loss of Spry1 expression impairs BRAF-mutant CM progression. Therefore, the extensive long and small ncRNA datasets generated in this study might represent a valuable resource for the characterization of their roles in BRAF-mutant CM initiation and progression upon Spry1 loss, thus providing a comprehensive resource to support future studies on BRAF-mutant CM.
皮肤黑色素瘤（CM）在全球范围内的发病率持续上升，是最具侵袭性的皮肤癌类型，导致了大多数与皮肤癌相关的死亡。大约50%的CM携带激活型BRAF突变，尽管BRAF抑制剂已显示出临床疗效，但大多数患者通常会对治疗产生早期耐药性。非编码RNA（ncRNA）的异常表达（其在整个转录组中占比不到2%）与CM的发生和发展有关。通过使用BRAF突变型CM的体外和体内模型，我们最近证明Spry1表达缺失会损害BRAF突变型CM的进展。因此，本研究中生成的大量长链和小ncRNA数据集可能是表征它们在Spry1缺失时BRAF突变型CM起始和进展中作用的宝贵资源，从而为支持未来关于BRAF突变型CM的研究提供全面的资源。
